Compare Sana Biotechnology Inc (SANA) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while YieldMax Universe Fund of Option Income ETFs trades at $7.61 (market cap $364M). The key difference: Sana Biotechnology Inc is far larger — about 2.3× YieldMax Universe Fund of Option Income ETFs's market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,181,378). Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and YieldMax Universe Fund of Option Income ETFs for 56 Days on average.
| SANA | YMAX | |
|---|---|---|
Market Cap | $836.71M | $364M |
Volume | 4,507,444 | 1,181,378 |
Sector | Health | Income / Options Overlay |
52-Week High | $5.92 | $12.70 |
52-Week Low | $2.68 | $7.27 |
Typical Hold Time | 23 Days | 56 Days |
Enterprise Value | $749.96M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
YMAX trades at $7.48, down 0.66% with a bearish technical outlook showing 18 sell signals versus 2 buy signals. The ETF faces fundamental challenges with declining NAV and concerns about distribution sustainability despite offering high yields. Recent news highlights weekly dividend distributions but also raises questions about the fund's structure and cost efficiency.
The outlook remains cautious due to persistent NAV erosion and structural concerns. While the high distribution yield attracts income investors, the fund's declining share price and potential for reverse splits present significant risks. Investors should weigh the attractive income against the potential for principal erosion in this complex ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
